You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| SAND GROVE CAPITAL MANAGEMENT L | 1,501,205 | 9. | 1,501,205 | 11. | 1,501,205 | 4.3% |
Follow Simon Davies's Sand Grove Capital Partners
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 1 of 4 – SEC Filing
| UNITED STATES |
| SECURITIES AND EXCHANGE COMMISSION |
| Washington, D.C. 20549 |
| SCHEDULE 13D |
| Under the Securities Exchange Act of 1934 |
| (Amendment No. 1)* |
| SYNERON MEDICAL LTD |
| (Name of Issuer) |
| Common Stock |
| (Title of Class of Securities) |
| M87245102 |
| (CUSIP Number) |
| Jonathan Groom |
| 4th floor, 35 Dover Street |
| London |
| W1S 4NQ |
| +44 (0) 203 770 8613 |
| (Name, Address and Telephone Number of Person |
| Authorized to Receive Notices and Communications) |
| 10 May 2017 |
| (Date of Event which Requires Filing of this Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Syneron Medical Ltd. (NASDAQ:ELOS)
Follow Syneron Medical Ltd. (NASDAQ:ELOS)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 4 – SEC Filing
| CUSIP No. M87245102 | 13D | Page 2 of 4 Pages |
| 1. | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) SAND GROVE CAPITAL MANAGEMENT LLP | |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☐ (b) ☒ | |
| 3. | SEC USE ONLY | |
| 4. | SOURCE OF FUNDS (see instructions) OO | |
| 5. | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐ | |
| 6. | CITIZENSHIP OR PLACE OF ORGANIZATION United Kingdom |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7. | SOLE VOTING POWER 1,501,205 | |
| 8. | SHARED VOTING POWER | ||
| 9. | SOLE DISPOSITIVE POWER 1,501,205 | ||
| 10. | SHARED DISPOSITIVE POWER |
| 11. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,501,205 | |
| 12. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐ | |
| 13. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.3% | |
| 14. | TYPE OF REPORTING PERSON (see instructions) PN |
Follow Syneron Medical Ltd. (NASDAQ:ELOS)
Follow Syneron Medical Ltd. (NASDAQ:ELOS)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 4 – SEC Filing
| CUSIP No. M87245102 | 13D | Page 3 of 4 Pages | ||
Item 1. Security and Issuer.
Item 2. Identity and Background.
Item 3. Source or Amount of Funds or Other Consideration.
Item 4. Purpose of Transaction.
Item 5. Interest in Securities of the Issuer.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Item 7. Material to Be Filed as Exhibits.
Follow Syneron Medical Ltd. (NASDAQ:ELOS)
Follow Syneron Medical Ltd. (NASDAQ:ELOS)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 4 – SEC Filing
| CUSIP No. M87245102 | 13D | Page 4 of 4 Pages | ||
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| COMPANY NAME | ||
| Sand Grove Capital Management LLP | ||
| Insert Name | ||
| Daniel McLachlan – Operations Analyst | ||
| Insert Title | ||
| 11 May 2017 | ||
| Insert Date |
Follow Syneron Medical Ltd. (NASDAQ:ELOS)
Follow Syneron Medical Ltd. (NASDAQ:ELOS)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
